

ev3's Strategic Planning and Alignment Process "Doing the Right Things.... Right"

Dave Mowry, President Neurovascular Division Irvine California



Level Setting A Brief History of ev3

- Venture Funded Minneapolis MN Start-up, founded in 2000
- Founders Group of disempowered / disgruntled Medical Device Professionals
 - "Wanted to Created a Place where everyone could make a difference"
- Business Model → Acquire & Develop products specifically for unmet needs
 - Cardiovascular,
 - Peripheral Vascular, and
 - Neurovascular

- 3 Endovascular Markets = EV3
- Re-focused & Dedicated to the underserved PV and NV Markets in 2003.
- Growth fueled by a steady flow of Organic Development & Acquisition
 - Microvena (Minneapolis, MN) 2003
 - MTI (Irvine, CA) 2005
 - FoxHollow Technologies (Redwood City, CA) 2007
 - Chestnut Medical Technologies (Menlo Park, CA) 2009



Our Strategic Planning Efforts were retooled in 2008 at a pivotal point in our company's existence

ev3 in early 2008


- On the end of a tough M&A integration
- Unrealistic goals & inconsistent performance
- Reactive, "Fire-fighting" culture
- Lack of external credibility
- Unsatisfied Constituents
 - Customers
 - Employees, and
 - Shareholders





Enter a Man and a Vision

- Bob Palmisano, CEO
- HPMS High Performance Management System
 - A single page strategic plan......
 - Aligns resources to "Vital Few" Initiatives
 - integrates Corporate Priorities with Individual





What is the High Performance Management System and how does it fit within Strategic Planning?



The integrated process by which a company involves and aligns its employees in accomplishing the goals and objectives of the organization.



The HPMS is built on Shared Values – The Values selected are designed to transform the organization

Customer 1st

Customer needs are understood and considered in every decision. We ensure every customer contact, both internal and external, is accurate, respectful, prompt and meaningful.

Empowerment

We establish clear objectives, surround ourselves with talented people, and then get out of their way.

Accountability

We say what we will do, and do what we say. We reach agreements and hold each other equally accountable.

Teamwork

We achieve results through open collaboration where the talents of each team member enable the greater success of the team.

Candor

We express our honest intentions in everything we do.

Sense of Urgency

The Vital Few programs are our top priority; we reject complacency, embrace change and courageously confront obstacles to deliver on-time results.

Continuous Process Improvement

We seek to continually increase our efficiency by following a disciplined approach to assess and improve our business processes; we seek breakthrough improvements and Best in Class performance.

... and focuses on delivering value to the company's three constituents in a balanced scorecard approach.

DELIGHTED CUSTOMERS

MOTIVATED EMPLOYEES

SATISFIED SHAREHOLDERS









SUCCESS




The Success Cycle



HPMS Strategic Planning Process Overview Step 1: Determining Current State - Where are we today?



Market Model



Competitive Summaries



Customer Survey



Employee Survey

1. I am delighted by the c	ooperation a	ind feamwork d	emonstrated I	ny Peripheral 1	/ascular:	
Department	Totaly Ag ee	Scmewhat Agree	TA + \$A	70+68	Somewhat Disagree	Totally Disagree
Clinical A l'airs	31.0%	58.3%	87.3%	12.7%	9.5%	3.2%
Facilities I/ aintenance	36.8%	56.0%	92.7%	7.3%	8.6%	0.7%
IV -manos	23.6%	53.4%	77.1%	22.9%	15.4%	1.5%
PV luman Resources	32.3%	50 454	72 896	17.2%	12.2%	7.0%
Plymout r Mfg Operations	30.7%	54.5%	85 2%	14.8%	11.0%	3.8%
PV Marketing	25.1%	51.1%	76.2%	23.8%	15.8%	3.0%
IV Quary	34.2%	54.7%	88 9%	11.1%	8.2%	2.8%
Plymouth Mfg Planning	23.0%	f/3 7%	77 3%	12 7%	0.506	4.2%
PV Process Devlant	29.9%	51.8%	8: 4%	18.8%	14.5%	4,1%
PV Reculatory	35.9%	51.6%	87.5%	12.5%	9.4%	3.1%
IN Research & Devipmi	27.0%	49.5%	76 5%	25.5%	16.5%	6.0%
HSPV Sales	10 4%	53 156	71.4%	20.6%	21.2%	7.0%
PV Div. Senior Staff	22.8%	54.8%	77 1%	22.9%	15,4%	7.4%

Financial Summaries

ev3 line. Income Statement 2004 - Adjusted Formal 2009 LINE SYSNIGHT												
Emilions National Cost of sales Gross profit Gross profit to sales	GT actual 5 (01) 33.4 67.6 (11.0)	67 100 1 1 107 1 1 107 1 1 107 1 1 107 1 1 107 1	1000 10000 1 00.5 33.4 92.1 00.3%	AF AF 64.05	60 1 27 1 27 1 27 1	886. 37.3 6 22.1 28.2 67.0%	27 LBR Bal. 127.2 36.7 F1.9 66.7%	800 70008 1 111.1 54.1 93.9 10.3%	94 LBR 1 (0.1 36.3 86.7 00.4%	800 70008 1 450.5 150.6 290.5 67.5%	Fall Year 1 430 1 1 140 2 5 201 2 201 25	#CPC
Setting Southern SUA FILE Circles Strategies Operating Engance	300 57 30 129 64 95	32 1 8.0 3.2 18.6 9.7 4.1	29.4 6.3 3.1 12.9 6.0 60.3	10 5 17 12 43 30 11	11 14 19 11 23 11	12 12 12 13 14 15 16 16	28.8 4.8 3.2 14.2 6.2 4.4 63.7	20.7 6.0 3.2 14.7 8.8 4.8	20.0 4.5 3.2 4.2 1.1 4.0 6.0	120.2 26.0 12.5 61.1 26.4 274.7	007 235 925 612 980 984	0 0 0
Ligation other regar there expenses those compensation Americalion Asset inspersivelt Total operating expenses	00 11 44 62	87 (8.0) 37 7,9 18.6	0.8 2.2 7.0 71.2	8.4 12 23 81	01 03 23	0.4 0.8 2.3 2.3 2.8	1.1 2.6 7.0 3.6 76.4	68 23 67	1.8 3.3 6.7 78.8	2.2 1.1 14.8 20.5 10.8 302.3	83 11 143 293 341	0.000
Operating Income(f,com)	(12.0)	(DE N	(5.1)	8.6	(4.1)	(3.4)	5.0	1.5	0.1	(40.7)	(45.0)	
Gain on sale of investments obsess procureyequesse, not FX transaction gueryesse. Todal other procures/expense.	0.40 0.40 0.80	2.4 0.1 0.2 0.0	- :	(A.)		9.7	(6.1) 2.0 2.0	- :	- :	0.4 0.4 0.6	(0.4) (0.3) 0.9	9
Important (Lose) (Malters Tax	0.0	(DK N)	(8.1)	6.7	(6.3)	(4.1)	0.6	1.5	0.1	(39.4)	(45.5)	-
ncome tax expense Net income(\$.com)	25	07.4	0.5 (5.4)	17	8.0	0.4 (4.5)	04.6	- 11	22	5 per 50	4 (M)	- 1
HTE Avg Stone - Prinary (nettine) HTE Avg Stone - Stuted (nitions)	104.1	104.0	104.4	104.4	104.9	104.8	104.6	104.6	194.8	104.4	194.2	
EFG - Drinary EFG - DisJect	\$ (0.00)	1 (0.20)	6 (0.05)	6 001	s (0.00) s	(E.04) S	0.10	5 0.01	\$ (0.00)	5 (0.40)	1 (40)	100
EBITCA. EBITCA, adjusted for Discit Complosey EBITCA, soji for Idoos Comp, Merger	6.1 7.5	(10.0) (10.0) (1.0)	13 53 59	13 12 12	(2.5) (2.5) (2.5)	(E3) 3.5 3.6	6.7 6.7	11.9 15.2 15.2	10.8	2.8 10.3 36.6	(23) 15.3 27.6	į
Albated Earlings Albated EPG	5 32 6 300	1 020	1 025	13	(2.1) (4.00 p	(1.0) (50) 1	635	11.1	9 911	13.8 6 0.12	1 100 1	, di


Timing

2X Year Spring / Fall




Your endovascular company."

HPMS Strategic Process Overview Step 2: Setting the Desired State - Where do we want to go?





HPMS Strategic Process Overview Step 3: Building our Plan - How will we get there?



Opportunity Tracker



Business Roadmap



Opportunity Form



Resource Model



Timing

2X Year\
Spring / Fall




HPMS Strategic Process Overview Step 4: Aligning our resources to the plan

Consolidated Portfolio and Financial Models | Statistic | Profession | 174 | 1864 | 1974 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1984 | 1

BM Stents	Position									
	Market Size	774	865	915	987	1,069	1,109	1,137	1,098	3
	Share	5%	7%	9%	11%	1196	12%	13%	14%	
	Revenue	37.7	63.5	86.0	106.3	122.6	135.4	145.6	151.9	9
	Growth		68%	36%	24%	15%	10%	8%	4%	
Balloons	Position									
	Market Size	338	348	369	401	441	477	491	488	5
	Share	196	3%	4%	5%	4%	5%	6%	7%	
	Revenue	4.5	11.6	16.4	20.6	15.5	22.3	29.4	34.4	14
	Growth		158%	42%	26%	-25%	44%	32%	17%	
Embolic Protection	Position									
	Market Size	145	158	162	167	181	198	204	210	6
	Share	4%	10%	14%	15%	14%	15%	15%	15%	
	Revenue	6.1	16.3	22.7	24.2	26.0	29.1	30.5	32.0	7
	Growth		166%	39%	7%	7%	12%	5%	5%	
Thrombectomy	Position									
	Market Size	109	110	120	124	131	134	142	147	4
	Share	6%	5%	3%	3%	196	0%	0%	0%	
	Revenue	6.5	5.0	3.3	3.3	0.8	0.6	0.5	0.4	-40
	Growth		-23%	-34%	-196	-77%	-24%	-12%	-17%	

wiodeis	Pi	ojection	s	Industry Comparison					
	2008	2009	2010	HG	MT	LCC	All		
Revenue	\$220M	\$280M	\$340M	\$337M	\$143M	\$6.1B	\$337M		
Gross margin	67%	70%	73%	69%	72%	71%	69%		
SG&A	55%	52%	47%	46%	55%	36%	39%		
R&D	13%	13%	13%	9%	13%	12%	11%		
Operating margin	(10%)	1%	10%	17%	(9%)	20%	16%		
Revenue growth	51%	10%	18%	21%	29%	11%	19%		
EPS	(\$0.10)	\$0.14	\$0.75	-	-	-	-		




Timing

2x Year Winter / Summer



Your endovascular company."

HPMS Strategic Process Overview Step 5: Implement our plan & connecting the organization



We have realized a significant turnaround in all three constituent groups

